To standardize and guide the clinical trial design and endpoint selection of drugs for the treatment of advanced non-small cell lung cancer in China, and provide referable technical specifications, NMPA hasorganized the formulation of and released on September 18, 2019 theTechnical Guidelines for Endpoints in Clinical Trials for Advanced Non-Small Cell Lung Cancer.